ABX-1488

ABX-1488 is an investigational positron emission tomography (PET) radiotracer that selectively binds monoacylglycerol lipase (MAGL) to enable noninvasive imaging and quantification of MAGL expression and occupancy in the human brain. Developed originally by Abide Therapeutics and later advanced by Lundbeck, the agent is labeled with fluorine-18 and is intended as a monoacylglycerol lipase–specific PET ligand to support central nervous system drug development targeting the endocannabinoid system, including MAGL inhibitors. Early first-in-human studies have evaluated its safety, test–retest reproducibility, and radiation dosimetry in healthy volunteers, and a PET occupancy study has been conducted to characterize brain MAGL engagement.

Other names

[18F]ABX-1488fluorine-18 ABX-1488fluorine18 ABX-1488fluorine 18 ABX-1488